Hims & Hers Health (HIMS) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GeneDx (WGS) has outperformed Hims & Hers Health (HIMS) over the past year, losing 44.8% versus a loss of 51.8%. Over five years, HIMS leads with a +235.6% price change compared with -73.7% for WGS. Hims & Hers Health is the larger company by market cap ($7.23 billion vs $2.01 billion), about 3.6 times the size.
On valuation, Hims & Hers Health trades at a lower forward P/E (42.1x vs 56.2x for GeneDx). Hims & Hers Health converts more of its revenue into profit, with a net margin of 5.5% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIMS | WGS |
|---|---|---|
| Share price | $31.01 | $67.30 |
| Market cap | $7.23B | $2.01B |
| 1-day change | +10.50% | -0.63% |
| YTD return | -13.58% | -47.92% |
| 1-year return | -51.76% | -44.80% |
| 5-year return | +235.65% | -73.65% |
| Forward P/E | 42.06 | 56.15 |
| EPS (TTM) | $-0.64 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.35B | $427.54M |
| Revenue growth (YoY) | +59.00% | +39.97% |
| Net income (latest FY) | $128.37M | $-21.02M |
| Gross margin | 73.84% | 69.74% |
| Operating margin | 4.50% | -3.06% |
| Net margin | 5.47% | -4.92% |
| 52-week high | $65.30 | $170.87 |
| 52-week low | $13.74 | $32.21 |
| Distance from 52-week high | -52.52% | -60.61% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +0.46% | +38.93% |
| Average volume | 12.05M | 730.21K |
| Shares outstanding | 224.94M | 29.82M |
| Employees | 2,442 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Hims & Hers Health is about 3.6 times larger than GeneDx by market value ($7.23B vs $2.01B).
- Hims & Hers Health is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- Hims & Hers Health grew revenue faster in its latest fiscal year (+59.00% vs +39.97%).
About Hims & Hers Health
HIMS stock →Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally.
Health Care · Medical/Nursing Services · 2,442 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
HIMS vs WGS FAQ
Which is bigger, Hims & Hers Health or GeneDx?
Hims & Hers Health (HIMS) is larger, with a market capitalization of $7.23B compared with $2.01B for GeneDx (WGS).
Which stock has performed better over the past year, HIMS or WGS?
WGS returned -44.80% over the past 12 months, compared with -51.76% for HIMS (price return, excluding dividends). Past performance does not predict future results.
Are Hims & Hers Health and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.